India Pharma Market
7 articles on India Pharma Market, written by Shotlee and medically reviewed for clinical accuracy.
IPM Growth Accelerates to 10.1% as GLP-1 Generics Reshape India's Anti-Diabet...
India's pharmaceutical market (IPM) surged 10.1% year-on-year in March 2026, with anti-diabetic therapies leading at 15.5% growth thanks to generic semaglutide entries. The GLP-1 agonist segment exploded to Rs 15.8 billion in MAT March, nearly tripling YoY. Ind-Ra forecasts sustained 9-10% IPM growth in FY27 amid chronic therapy dominance.
4 min read
Emcure Slashes Poviztra Price 55% in Semaglutide India Price War
Emcure Pharmaceuticals has dramatically reduced Poviztra prices by 55% for the starting dose, fueling a semaglutide price war in India after patent exclusivity lapsed. This move positions the branded pen injector competitively against generics priced as low as Rs 1,200-1,500 per month. With obesity rates rising, these changes could widen access to this proven weight-management therapy.
4 min read
Ajanta Pharma, Sun Pharma Poised for GLP-1 Opportunity in India Market Shift
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
4 min read
Semaglutide Prices Drop 70-90% in India After Generic Launches by Sun Pharma,...
Semaglutide prices in India have plummeted by up to 90% following the launch of over 15 generic versions just days after patent expiry. Major players like Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco are offering affordable options for type 2 diabetes and obesity management. This shift promises greater access to this vital GLP-1 agonist therapy.
6 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
Abbott Partners with Novo for Semaglutide Extensior in India
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
4 min read
Can GLP-1 Drugs Power Healthify's Coaching Future? Semaglutide Shift
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
5 min read